Q4 2010

Filed Mar 16, 2011 · 10-K · 75 days after period end · 0001157523-11-001610

Q4 2010 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—

Net income—

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived$3,769,096—

Free Cash Flowderived$2,801,835

Same quarter

no prior Q4 2009 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2010 · filed Mar 16, 2011 · 75 d after period end

Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR